Lixte Biotechnology Shares Up After Announcing Preclinical Results of its Collaboration with the Netherlands Cancer Institute
Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) shares jumped more than 280% after the company announced new data from promising drug combinations of LIXTE’s lead clinical cancer compound, LB-100, at the Annual Meeting of American Association for Cancer Research (AACR) in...